Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
Purdue Pharma L.P. announced today the presentation of results from six clinical and non-clinical research studies at the Academy of Managed Care Pharmacy Managed Care& Specialty Pharmacy Annual Meeting 2017 in Denver, Mar. 27-30, 2017. We are pleased to present results from several studies that show our commitment to the pain community while ad
PARIS- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis or AD whose disease is not adequately controlled with topical prescription therapies, or.
March 28 Type 2 diabetes has been reversed in mice with a new, orally available drug, according to a study led by San Diego scientists. The study suggests a path for developing human therapies based on the drug. Scientists led by physician-researcher Nunzio Bottini countered insulin resistance by designing a drug that restored the effectiveness o
We achieved significant progress in 2016, including securing two partnerships with world renowned pharmaceutical groups that ensure the focused development of our disruptive immunotherapies for auto-immune disorders. said Dominique Costantini, CEO of OSE Immunotherapeutics. In addition, we met key preclinical and clinical development goals
NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program. ORIEN Avatar is a collaboration between the 15 leading U.S. ca
By a News Reporter-Staff News Editor at China Weekly News- AbbVie, a global biopharmaceutical company, announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir for the treatment of all major genotypes of the chr
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150& 500 mg, an AB-rated generic vers
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Dr. Shetty is a pharmaceutical industry executive with 36 years of experience at Johnson& Johnson and its subsidiary Janssen. Most recently Dr. Shetty served as the H
Adamas Pharmaceuticals, Inc. today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia in patients with Parkinson s disease, to be presented at the Academy of Managed Care Pharmacy s 2017 Annual Me
Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson s disease is und
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Health
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., today announced three additions to the company's board of directors:. Mr. Gabrieli will serve as chairman of the board of Akcea Therapeutics. Elaine Hochberg, former chief commercial officer of Forest Laboratories. Sandford D. Smith, founder and chairman of Global Biolink Partners..
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, today announced the publication of positive results from a Phase 2 a study of vadadustat, a once-daily oral HIF stabilizer in development for the treatment of anemia relat
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16 th Annual Needham Healthcare Conference at 5:00 p.m. ET on Tuesday, April 4, 2017 in New York, NY. Alder BioPharmaceuticals, Inc., is a clinical-stage...
Allergan, a leading global pharmaceutical company and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that management will present a company overview at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company...
AMAG Pharmaceuticals, Inc. today announced that management will present at the 16 th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.. A live audio webcast will be accessible through the Investors section of the company s website at www.amagpharma.com, and will be archived for 30 days. AMAG Pharmaceuticals Contac
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus infection, has raised a $22 million Series C financing led by Brace Pharma Capital with participation from new investors NS Investment, Osage University Partners and Alexandria Venture..
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations,
Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the fourth quarter and year ended December 31, 2016 as well as recent corporate progress. In 2017, we look forward to completing study enrollment, engaging in discussions with the FDA to deter
AstraZeneca today announced that the US Food and Drug Administration has accepted the company s New Drug Application for LYNPARZA? tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA grants Priority Review to applications for medicines that treat serious conditions and, if approved, would